The IPO, which closed on July 22, was subscribed 116 times at a price band of Rs 880-896 per share.
"Effective from Monday, August 1, 2016, the equity shares of Advanced Enzyme Technologies Ltd shall be listed and admitted to dealings on the exchange in the list of 'B' Group of securities," BSE said in a circular.
The quota reserved for qualified institutional buyers (QIBs) was oversubscribed 94.03 times and that of non institutional investors' 393.10 times. Retail investors category was oversubscribed 11.6 times.
ICICI Securities and Axis Capital were the lead managers of the issue.
The company is the leading domestic enzyme firm engaged in research, development, manufacturing and marketing of over 400 proprietary products developed from 60 indigenous enzymes.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
